Zydus Lifesciences Limited reported earnings results for the third quarter and nine months ended December 31, 2025. For the third quarter, the company reported revenue was INR 69,759 million compared to INR 53,266 million a year ago. Net income was INR 10,421 million compared to INR 10,235 million a year ago. Basic earnings per share from continuing operations was INR 10.36 compared to INR 10.18 a year ago. Diluted earnings per share from continuing operations was INR 10.36 compared to INR 10.18 a year ago. Basic earnings per share was INR 10.36 compared to INR 10.17 a year ago. Diluted earnings per share was INR 10.36 compared to INR 10.17 a year ago.
For the nine months, revenue was INR 199,367 million compared to INR 169,025 million a year ago. Net income was INR 37,675 million compared to INR 33,546 million a year ago. Basic earnings per share from continuing operations was INR 37.44 compared to INR 33.34 a year ago. Diluted earnings per share from continuing operations was INR 37.44 compared to INR 33.34 a year ago. Basic earnings per share was INR 37.44 compared to INR 33.34 a year ago. Diluted earnings per share was INR 37.44 compared to INR 33.34 a year ago.
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
